Skip to main content
OpenTrials
Completed

NCT Number: NCT03087188

Inhalation Therapy in Ambulant and Hospitalized Patient Using Available Film Sequences From the Internet

There are different therapy strategies for patients suffering on obstructive lung disease like chronic obstructive pulmonary disease (COPD), and asthma bronchial available. One of these strategies includes inhalative drugs, e.g. ß2-mimetics, anticholinergic drugs, or glucocorticoids, which are indicated often and which can be used with different inhalation devices. Dry powder inhalators, and dosieraerosol are used the most in clinical routine. Further strategies in treating obstructive lung disease are innovative systems like Respimat or systems with liquid inhalation. However, the success of the therapy depends on the correct application technique. In the clinical routine a high error rate was observed. Consequently, the initiative of the German league of respiratory tracts published internet-based film sequences in order to demonstrate how to use an inhalator correctly. These films are available in the internet for everyone and can be watched as often as needed in order to improve technique and facilitate training.

Therefore, in this study we aim to evaluate the following aspects:

* amount of wrong applications in ambulant and hospitalized patients (wrong in terms of lack of knowledge on how to use the inhalator or incorrect utilization) * amount of correct applications in patients who had first used the inhalator incorrectly but improved technique by watching the film sequences * evaluation of learning success within 2 weeks to 2 months (follow-up visit in the ambulance)

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • male and female patients indicated for inhalative treatment with ß2-mimetics, inhalative steroids, anticholinergic drugs, or a combination of these drugs
  • patient was already trained on how to use the inhalator before participating in the study
  • age > 18
  • obtained written consent

Exclusion criteria

  • patients who are incapable to consent or are unable to understand the scope of the trial
  • patients who indicate that they do not know how to use the inhalator

Treatment and study plan

Utilization of inhalator

Other

After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.

While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them.

Primary outcomes

  1. Correct utilization of inhalator

    Time frame: Day of Screening and follow-up visit (2-8 weeks)

    Wrong utilization is determined as lack of knowledge on how to use the inhalator or incorrect application

Sponsors and collaborators

Lead sponsor

RWTH Aachen University

Other

Registry information

Acronym: InhaliPAD

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Mar 22, 2017
Registry last updated
Mar 22, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.